FDA Label Change Takes a Bite Out of Prescriptions

November 26, 2019 – Immunotherapy prescriptions for patients with metastatic bladder cancer declined rapidly after the FDA altered the indications of 2 drugs, suggesting that practicing oncologists can keep pace with changes associated with the agency’s accelerated approval program. Data published in JAMA showed that usage rates for pembrolizumab and atezolizumab in this population dropped by approximately 40% within 8 months of a label change. The uptake … (leggi tutto)